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Graves' Disease Following the Occurrence of Hypothyroidism 
A. R. Guansing, MD,* D. D. Klink, MD,* N. Engbring, MD,** Y. Leung, MD,*** 
J. chakravarty, MD,*** and S. Wilson, MD** 
Three patients with hypothyroidism of 15-48 months' dura-
tion developed Graves' disease while on thyroid hormone 
replacement therapy. In one patient, the hyperthyrold 
phase was preceded by ophthalmopathy and nonsuppres-
slble 24-hour radioactive iodine uptake (RAIU). Eventually, 
all had hyperthyrold findings with elevated thyroid hor-
mone levels, high 24-hour RAIU, and a diffuse uniform 
uptake of RAI by the enlarged thyroid. All subjects had 
negative antithyroglobulin and antimicrosomal antibody 
titers. Two had demonstrable long-acting thyroid stimulator 
(LATS) in their sera. All three were followed for 5-36 
months while on propylthiouracil therapy prior to surgery 
or RAI administration. Both LATS-positive patients under-
went bilateral subtotal thyroidectomy. Classical changes of 
Graves' disease were found on histopathological examina-
tion of resected tissues. 
T h e occurrence of Graves' disease after a period of hy-
pothyroidism is an unusual phenomenon. Since 1930, the 
English literature describes almost 80 patientswith Graves' 
disease following use of thyroid extract or synthetic thyroid 
hormone (1-11). However, only 24 had substantial evi-
dence that suggested prior hypothyroidism, and of the 24, 
14 had well-documented evidence to support the diagnosis 
(6-16). In the majority of patients, obesity was the primary 
indication for thyroid hormone therapy (1-3). Attention was 
therefore focused on the possible association of prior thy-
roid extract therapy and the subsequent development of 
"exophthalmic goiter" with hyperthyroidism. Not until 
1967 were autoimmune mechanisms considered a possible 
cause of hyperthyroidism in this subset of patients (4). This 
report deals with three cases of Graves' disease following 
unequivocal hypothyroidism which can be best explained 
on the basis of autoimmune mechanisms. 
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Patients and Methods 
Three patients with a history of hypothyroidism were re-
ferred to The Medical College of Wisconsin for mani-
festations of hyperthyroidism while they were on thyroid 
hormone replacement therapy. 
The clinical history and physical findings during the dis-
ease period were reviewed, as well as the laboratory 
procedures performed before and during thyroid hormone 
therapy. The diagnosis of hypothyroidism was verified in all 
three patients with the determination of serum protein-
bound iodine (PBI) and/or serum thyroxine (T4) levels 
together with Ts-resin uptake (T3RU). Initial 24-hour ra-
dioactive iodine uptake (RAIU) tests were performed on 
two patients before therapy. 
All three patients were seen one to three months after their 
thyroid hormone medication had been discontinued. A 
complete history and thorough physical examination were 
made on each patient and appropriate thyroid function 
studies were performed. Serum triiodothyronine (T3) and T4 
were measured by standard radioimmunoassay procedures 
(17,18). Serum T3RU values were determined with a com-
mercially available kit (Abbott Laboratories, North Chi-
cago, IL) except when otherwise indicated. The free 
thyroxine index (FTI) was calculated for each of the sub-
jects (19). Radioimmunoassay for serum TSH was carried 
outwith commercially available materials (Beckman Com-
pany, Fullerton, CA). Thyroid antibodies were checked with 
the hemagglutination techniques for antithyroglobulin and 
antimicrosomal antibody determinations (20,21). An im-
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munofluorescent antibody technique was also employed 
for patients 2 and 3 (22). Werner's suppression test was 
used in patient 3, with 50% suppressibility of RAIU as the 
minimal criterion for response (23). The presence of a long-
acting thyroid stimulator (LATS) in serum was verified by 
Bioscience Laboratories (Van Nuys, CA) using the 
McKenzie method (24). RAI uptake and scans were per-
formed for all three subjects. 
Propranolol, a beta-adrenergic block agent, was given for 
symptomatic relief, and propylthiouracil (PTU) was admin-
istered in appropriate doses to the patients over a period of 
5-26 months. Subsequently, bilateral subtotal thyroidec-
tomy was performed on two patients, and RAI therapy was 
instituted on the third. 
Results 
Hypothyroid phase 
Table 1 summarizes some of the clinical and laboratory 
features of the three patients. 
Patient 1 was found to have an "adolescent goiter" 14 
months before clinical hypothyroidism developed. Her 
serum PBI atthe time was 6.2 /x,g/dl (n =2.5-6.7 /u-g/dl), and 
the T3RU was 29.1% (n =25-35%). Then at age 11 she 
developed progressive weight gain, cold intolerance, slug-
gishness, dry skin, coarse scalp hair, puffy eyelids, and 
persistence of thyromegaly. Her serum PBI decreased to 1.3 
ju,g/dl with a T3RU of 20%. When desiccated thyroid was 
started at a maintenance dose of 3 gr/day, all of her 
symptoms improved, she gained weight, and her goiter 
disappeared. Menarche began at age 12 with normal men-
strual cycles. The desiccated thyroid was gradually de-
creased and finally discontinued after 35 months when she 
developed signs of hyperthyroidism. 
Patient 2 presented with signs and symptoms of hypo-
thyroidism, but no thyromegaly was found. On 2-3 gr of 
desiccated thyroid daily, all signs and symptoms disap-
peared unt i l 48 months later when he developed 
hyperthyroidism. 
Patient 3 presented with mild symptoms of cold intolerance 
and tiredness at age 54 but few physical findings. He did 
not have thyromegaly. He was treated with 0.2 mg of L-
thyroxine unt i l 15 months later when he developed 
gynecomastia, exophthalmos, and diplopia without signs 
and symptoms of hyperthyroidism. The L-thyroxine was 
promptly discontinued. 
None of the patients were taking any iodide preparation. 
Family histories revealed that the mother of the first patient 
had required thyroid medications for approximately three 
months during her mid-thirties. She is now euthryoid and 
without any evidence of goiter. Patient 2 did not have a 
family history significantly related to hyperthyroidism. The 
father of patient 3 had undergone surgery for a goiter which 
was benign. 
Hyperthyrold phase 
Table 11 illustrates the salient clinical and laboratory find-
ings at the time hyperthyroidism developed, and Table III 
shows other laboratory procedures performed during the 
initial phase. 
Patient 1 developed a progressive weight loss of 11 pounds 
in two months with generalized weakness, increased ner-
vousness, irritability, and heat intolerance. She was nor-
motensive with a tachycardia of 90/minute. There was lid-
lag and diffuse thyromegaly with soft to firm consistency. 
She had an estimated weight of 60 gm. A bruit was present 
over the goiter. Her skin was moist, and fine tremors of both 
hands were observed. The remainder of her physical exam-
ination was within normal limits. Results o f the laboratory 
studies are shown in Table 11. Over the next 35 months her 
serum TSH levels varied from 4.1 p.U/m\ to 10.9 jU,U/ml, 
depending on the amount of PTU medication she was 
taking. 
Patient 2 presented with a progressive weight loss of 30 
pounds and severe weakness of the lower limbs. On physi-
TABLEI 
Clinical Findings During the Hypothyroid Phase 
Patient Sex 
Age of onset 
(years) Presenting symptoms 
PBI 
(2.5-6.7/ig/dl) 
T4 
(5.5-14^g/dl) T3RU 
24-hour RAI 
uptake (10-35%) 
1 11 
"Adolescent" goiter preceded 
hypothyroidism x 14 months; 
weight gain; cold intolerance 
1.3 — 
20% 
(25-35%) 1% 
2 M 12 Fatigue; cold intolerance; 
puffy eyes 
1,5 1.0 — 4% 
3 M 54 Cold intolerance — 1.8 35% 
(43-60%) 
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TABLE II 
Clinical and Laboratory Features During the Hyperthyrold Phase 
Patient Sex 
Age of onset 
(years) Salient findings 
Serum T4 
(4-11.5Mg/dl) 
Serum T 
(70-215 ng/ml 
T3RU 
(25-35%) 
TSH 
(<10/xU/ml) 
F 
M 
M 
14 Diffuse goiter; tremors; 19.4 
tachycardia 
16 Diffuse goiter; tachy- 27.4 
cardia; severe myopathy 
Mild thyromegaly 
56 exophthalmos and diplopia; 14.5 
gynecomastia 
380 
570 
42% 
44% 
41% 
2.2 
6.4 
3.8 
cal examination, he was tachycardic at 110/minute, with a 
normal blood pressure (124/80 mmHg). Lid-lag was bilat-
eral. A diffuse goiter was found. The remainder of the 
physical findings were within normal limits except for 
severe pelvic girdle muscle weakness with lesser involve-
ment of the distal musculature. Electromyography showed 
low voltage with polyphasic potentials consistent with 
myopathy. Cerebrospinal fluid findings were normal. Table 
II shows the results of the laboratory findings. At the end of 
10 months his serum TSH decreased to 2.8 ptU/ml together 
with a return to normal of both serum T4 and T3. Skull x-
rays showed a normal sella turcica. 
Patient 3 initially presented with exophthalmos, diplopia, 
and unilateral gynecomastia w i thout galactorrhea. 
Werner's suppression test showed an initial 24-hour RAIU 
of 30% and a subsequent value of 38% at the end of 10 
days of triiodothyronine, 75 /Ag/day in three divided doses 
(Table 111). One month later he developed manifestations 
of hyperthyroidism. He lost 12 pounds and was found to 
be mildly tachycardic (HR=90/minute). Eye findings in-
cluded marked limitation of upward gaze and limited 
lateral gaze bilaterally. Hertel exophthalmometry at base 
100 was 23 mm O D and 22 mm OS. A small goiter was 
found. Except for unilateral gynecomastia, physical find-
ings were otherwise unremarkable. Both testes were of 
normal size. Laboratory studies showed elevation of serum 
T4 to 14.5 Mg/dl, T3RU at 41%, and the FTI to 6.9. Three 
months later, while on PTU, he became euthyroid with 
both serum T4 and T3RU decreasing to 5.2 p.g/d\ and 25%, 
respectively, and serum TSH remaining normal at 
3.8 /xU/ml. On the fourth month his TSH increased to 
18 ptU/ml. PTU was discontinued. Excision of the gyneco-
mastia revealed normal breast tissue, and skull x-rays 
showed a normal sella turcica. 
As shown in Table IV, appropriate doses of propranolol 
and/or PTU were administered to the three patients for a 
period of 5-36 months. Bilateral subtotal thyroidectomy 
was recommended to patients 1 and 2 (who were still in 
their teens) at the end of one year of PTU therapy. At the 
request of patient 1 and her family, this was done three 
years later. At surgery, 170 gm of thyroid tissue was re-
sected; on histological examination, it showed pseudo-
papillary proliferation of tall columnar cells with some 
islands of lymphoid nodules scattered throughout. Actual 
lymphocytic infiltration was not observed. Patient 2 had a 
bilateral subtotal thyroidectomy after 12 months of PTU 
therapy. Histological findings were almost identical except 
for the weight of the tissue removed (160 gm). Patient 3 
received 10 mCi of RAI as ablative therapy when hyper-
thyroidism recurred at six months, after PTU had been 
discontinued for 30 days. All three patients were euthyroid 
on L-T4 replacement therapy 26-72 months after these 
procedures. 
Discussion 
Graves' disease following hypothyroidism is an unusual 
sequence of events that is not well recognized. In these 
three patients the clinical history and laboratory findings 
indicated hypothyroidism preceding hyperthyroidism. 
TABLE ill 
Other Laboratory Findings During Hyperthyroidism 
24-hour RAI uptake 
Patient LATS Anti-Tg Anti-M 
(10-35%) 
Thyroid scan 
1 (+) ( - ) ( - ) 51% Enlarged with 
uniform uptake 
2 (+) ( - ) ( - ) 79% Enlarged with 
uniform uptake 
30% "Normal" size 
3 NO (-) ( - ) 38%* uniform uptake 
* After 10 days of T3, 75 fig/day 
ND = not done 
LATS = long-acting thyroid stimulator 
Anti-Tg = antithyroglobulin antibody 
Anti-M = antimicrosomal thyroid antibody 
154 
Graves' Disease after Hypothyroidism 
TABLE IV 
Treatment Procedures During Thyrotoxic Phase 
Duration 
Patient First treatment (months) Second treatment Findings* 
1 PTU, 100 mg qid; propranolol, 
20 mg qid 
36 Bilateral subtotal 
thyroidectomy 
170 gm thyroid with pseudopapillary 
proliferation of columnar cells; 
lymphoid nodules 
2 PTU, 150 gm qid; propranolol, 
40 mg qid 
12 Bilateral subtotal 
thyroidectomy 
160 gm thyroid with similar histology 
as in No. 1 
3 PTU, 100 mg tid 5 10 mCi radioactive 
iodine 
— 
*Typical of Craves' disease 
PTU = propylthiouracil 
Their low serum PBI and T4 values and the definitely 
decreased 24-hour RAIU confirmed this diagnosis. How-
ever, as with most cases of hypothyroidism, the exact cause 
was not apparent. Aside from patient 1, whose small goiter 
occurred before the clinical findings of hypothyroidism 
were evident, the other two patients did not show any clues 
of "silent" or spontaneously resolving thyroiditis, subacute 
thyroiditis (which usually leads to transient hypothyroidism 
and, in rare instances, to permanent hypothyroidism), or of 
Hashimoto's thyroiditis, which has been implicated as the 
most frequent cause of this disorder. No patient had a 
history of prior hyperthyroidism. While goiter in childhood 
has been ascribed primarily to Hashimoto's thyroiditis (27), 
the subsequent antithyroglobulin and antimicrosomal anti-
body titers in our patients did not confirm this impression, 
although the relative insensitivity of the procedures em-
ployed might account for the negative results. The immu-
nofluorescent procedure, which is more sensitive but less 
specific for detecting thyroid antimicrosomal antibody, was 
also negative in two subjects (28). Since these studies were 
performed two to four years after the patients developed 
myxedema, significant titers might have been present at an 
earlier time. However, despite the development of signifi-
cant thyromegaly and the presence of appropriate antigens 
duringthe hyperthyrold phase, no anamnestic response in 
terms of higher and significant antithyroglobulin and anti-
microsomal antibody titers was observed. Furthermore, 
since histological findings in two patients were not charac-
teristic of Hashimoto's thyroiditis, it is doubtful that this 
disorder accounts for the initial phase of hypothyroidism. 
The possibility, however, of antibody-mediated TSH-recep-
tor blockade as an initial event could not be ruled out. 
As an alternative mechanism for the development of hy-
pothyroidism in these patients, TSH deficiency, with subse-
quent development of hyperthyroidism, has been de-
scribed in one case study (7). However, several factors in 
our three patients weaken these possible explanations: the 
subsequent menarche and normal menstrual periods after 
thyroid hormone therapy in patient 1, the normal skull 
x-rays of patients 2 and 3, and the appropriate changes in 
the circulating levels of TSH in all three patients during 
thionamide therapy, and subsequent surgery in the first two 
subjects. 
Immune-complex disease could also be implicated in the 
evolution of this problem. Although circulating immune 
complexes have been demonstrated for many thyroid dis-
orders, their pathogenetic significance has not been made 
clear except in glomerulonephritis (29,30). 
The evolution of Graves' disease is clearly evident in all 
patients. Classically, it consists of three components which 
occur simultaneously or independently: hyperthyroidism, 
infiltrative ophthalmopathy, and pretibial dermopathy (31). 
Patients 1 and 2 presented with hyperthyroidism only. Their 
physical findings, thyroid scans, and presence of LATS, a 
type of thyroid-stimulating immunoglobulin (33), all sug-
gested Graves' disease; histological findings bore this diag-
nosis out. In patient 3, Graves' disease presented with the 
infiltrative ophthalmopathic component followed by the 
hyperthyroid phase. Whether this was the ophthalmopathy 
of Hashimoto's or of Graves' disease is a moot point, since 
it has been described in both disorders (33,34). The nega-
tive Werner's suppression test during the patient's initial 
euthyroid phase suggests the presence of a thyroid-stim-
ulating immunoglobulin that caused a sufficient increase in 
thyroid hormone levels to suppress TSH secretion. TSI 
determinations, which could have confirmed this pos-
sibility, were not performed in this individual. However, 
the elegant studies of Solomon, et al (35) indicate that in 
euthyroid Graves' disease the relationship of thyroid-stim-
ulating immunoglobulins to thyroid nonsuppressibility is 
complex. 
While the thyroid disorder in our three patients undoubt-
edly evolved from a hypothyroid to a hyperthyroid phase, 
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we still do not understand the sequence of events. The 
evolution of Hashimoto's thyroiditis to Graves' disease is 
one consideration, which is supported by previous reports 
of the concurrence of Graves' disease and Hashimoto's 
thyroiditis in the same patient (32), the occurrence of these 
disorders in identical twins (36-38) and in families (39), and 
"Hashitoxicosis" (34,40). Our patients may represent a 
variant of Hashimoto's thyroid i t is w i thout the classic 
serological and histological findings. Since both disorders 
are considered to be autoimmune, the hypothesis of Voipe 
(41) could be modified to explain this evolution. The defect 
in immune surveillance (T-lymphocyte system), which 
could be spontaneous, stress- or viral-induced, permits 
organ-specific " J " lymphocytes to survive. They then in-
teract with complementary antigen (thyroid gland, orbital 
tissue, or pretibial skin in Graves' disease) to cause a cell-
mediated immune process in the target site. It is possible 
that a cytotoxic, destructive process, probably mediated by 
" J " or killer (K) lymphocytes directed at the thyroid gland, 
led to initial hypothyroidism in our patients. Subsequently, 
with continuing exposure of " B " lymphocytes to TSH 
receptors on thyroid cell plasma membrane, specific thy-
ro id-st imulat ing immunoglobul ins (TSI) were formed 
(42-45), perhaps aided by "helper" T lymphocytes as well . 
The presence of LATS, one type of TSI, in two patients, 
lends credence to this hypothesis, since TSI could then lead 
to a continuous stimulation of residual thyroid gland tissue 
that would cause sufficient hyperplasia and growth to 
account for the eventual hyperthyroid phase in our pa-
tients. However, for this situation to occur, the cytotoxic 
component of this dual immune response must for some 
reason fail so that the cytotrophic effect can prevail. 
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